Determination of the Quality of Life Instrument that is most preferred by patients with thyroid cancer
| ISRCTN | ISRCTN29843533 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN29843533 |
| Protocol serial number | 10323 |
| Sponsor | University Hospitals Coventry & Warwickshire NHS Trust (UK) |
| Funder | Macmillan Cancer Support (UK) |
- Submission date
- 10/08/2011
- Registration date
- 26/09/2011
- Last edited
- 30/04/2018
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Cancer
Plain English summary of protocol
Contact information
Scientific
University Hospitals Coventry and Warwickshire NHS Trust
Clifford Bridge Road
Coventry
CV2 2DX
United Kingdom
Study information
| Primary study design | Observational |
|---|---|
| Study design | Phase III, randomised, observational, qualitative trial |
| Secondary study design | Randomised controlled trial |
| Study type | Participant information sheet |
| Scientific title | Determination of which Health Related Quality of Life (HRQoL) instrument is most preferred by patients with early and advanced thyroid cancer |
| Study acronym | DeteQT |
| Study objectives | To determine which Health Related Quality of Life (HRQoL) instruments patients with early and advanced thyroid cancer find most helpful in facilitating communication of their health problems to their clinicians. |
| Ethics approval(s) | The Black Country Research Ethics Committee, 18th March 2011, ref: 11/WM/0051 |
| Health condition(s) or problem(s) studied | Head and neck cancer |
| Intervention | Patients are randomised to receive study instruments in varying order of presentation. There are no treatment arms or drugs used as it is a quality of life questionnaire study. The patients will be approached in the clinic where the trial will be explained to them and if they are interested, they will sign the consent form and take the questionnaire to complete and send back to us. |
| Intervention type | Other |
| Primary outcome measure(s) |
Patient preference: identification of preferred quality of life instrument |
| Key secondary outcome measure(s) |
No secondary outcome measures |
| Completion date | 12/07/2013 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | All |
| Target sample size at registration | 466 |
| Key inclusion criteria | 1. Patients 18 years old or over 2. Patients attending the thyroid or head neck cancer clinic who are: 2.1. Being treated or undergoing follow-up for differentiated (papillary or follicular) thyroid cancer or 2.2. Being investigated or treated for differentiated (papillary or follicular) thyroid cancer recurrence Note: patients with high grade variants such as insular carcinoma or poorly differentiated carcinoma are eligible 3. Male or female |
| Key exclusion criteria | 1. Patients who do not sufficiently understand the English language and those with learning disabilities as these are standardized and validated questionnaires which are in English 2. Patients who have medullary thyroid cancer or anaplastic thyroid cancer or lymphoma of the thyroid 3. Patients having a diagnostic hemithyroidectomy for possible thyroid cancer |
| Date of first enrolment | 28/07/2011 |
| Date of final enrolment | 12/07/2013 |
Locations
Countries of recruitment
- United Kingdom
- England
Study participating centre
CV2 2DX
United Kingdom
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
Editorial Notes
30/04/2018: No publications found, verifying study status with principal investigator.
04/03/2016: No publications found, verifying study status with principal investigator